ADC Therapeutics Q2 net loss widens to $56.6M; completes $100M PIPE, cuts workforce 30%

ADC Therapeutics SA

2025-Q2 EPS reported -$0.86 revenue$41,872,000

Q2 product revenue $18.1M (+6% YoY); net loss $56.6M ($0.50/share) vs $36.5M loss ($0.38) in Q2 2024.
Completed $100M PIPE with $93.1M net proceeds; cash $264.6M, expected runway into 2028.
LOTIS-7 (ZYNLONTA+glofitamab) showed 93.3% ORR, 86.7% CR in r/r DLBCL; expansion to 100 patients underway.
Strategic restructuring: discontinuing early solid tumor programs, shutting UK facility, workforce reduction ~30% by Sep 2025.
LOTIS-5 Phase 3 on track to reach PFS events by end of 2025; sBLA filing expected H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.